IGF-1 LR3: What the Research Actually Shows

What is IGF-1 LR3?

IGF-1 LR3 is an engineered version of insulin-like growth factor 1, built to resist the binding proteins that normally hold natural IGF-1 in check.

Natural IGF-1 is a hormone that sits downstream of growth hormone. When GH signals the liver and other tissues, much of GH's effect on growth and repair is carried out by IGF-1. The "LR3" label describes two structural changes: a 13-amino-acid extension added to the N-terminus (the sequence MFPAMPLLSLFVN, the "Long" part) and a single amino-acid swap at position 3, arginine in place of glutamic acid (the "Arg3" part). With those additions the molecule runs to 83 amino acids versus 70 in native IGF-1 (IGF-1 LR3, Wikipedia; Cayman Chemical product record). Both changes are meant to lower how tightly the peptide binds to IGF binding proteins.

That structural description is background, not a clinical finding. IGF-1 LR3 is distributed as a cell-culture and laboratory reagent, and independent human pharmacology for the analog specifically is not established in the literature. When you see confident numbers attached to it, treat them as extrapolation rather than trial data.

How is IGF-1 LR3 different from natural IGF-1?

The two changes are meant to reduce how strongly IGF-1 LR3 sticks to IGF binding proteins, so more of it stays unbound and active.

Natural IGF-1 circulates mostly bound to carrier proteins, chiefly IGFBP-3, which regulate its activity and how fast it is cleared. Reference sources describe IGF-1 LR3 as having very low affinity for the IGFBPs, with roughly threefold greater potency than native IGF-1 attributed to that reduced binding (IGF-1 LR3, Wikipedia). In principle, less binding means more free peptide and a longer active window. This is the design rationale reported by reagent and reference sources. It is not the same as a demonstrated human effect, because the analog itself has not been through the trial process that would confirm it.

What does the research actually show for IGF-1 LR3?

Very little in humans: controlled clinical trials of the IGF-1 LR3 analog are not in the peer-reviewed literature, so the honest starting point is a data gap.

What can be said with citations comes from the broader GH and IGF-1 axis, studied through secretagogues and GHRH analogs rather than through direct IGF-1 injection:

• CJC-1295, a long-acting GHRH analog, raised mean GH about 2 to 10 fold for 6 days or more and IGF-1 about 1.5 to 3 fold in healthy adults (Teichman et al., JCEM 2006; doi:10.1210/jc.2005-1536).
• Ipamorelin acts as a selective GH secretagogue, releasing GH without meaningfully raising cortisol or prolactin (Raun et al., Eur J Endocrinol 1998; PMID 9849822).
• Tesamorelin, a GHRH analog, reduced visceral adipose tissue about 15 percent versus a rise on placebo over 6 months in trial participants (Falutz et al., NEJM 2007; doi:10.1056/NEJMoa072375).

Each of these raises IGF-1 through the body's own machinery. That is a different route than administering an IGF-1 analog directly, and none of them validate IGF-1 LR3. For the analog itself, there is no equivalent human trial base to point to.

What dose of IGF-1 LR3 has research reported?

No completed human trial reports a therapeutic dose of IGF-1 LR3; it is handled as a research reagent, and there is no research-reported human figure for it.

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation. Because there is no research-reported human dosing for the analog itself, the table sets it against the adjacent, better-studied axis compounds so you can see where the actual human evidence sits and where it does not.

The takeaway from the table is not a number to copy. It is that the compounds with human data act on the axis indirectly, while the direct analog has essentially no human data behind it.

What is the half-life of IGF-1 LR3?

The LR3 design is meant to extend how long the molecule stays active by loosening its grip on IGF binding proteins, but a measured human half-life for this specific analog is not established in the literature.

The logic is that free IGF-1 clears quickly, while IGF-1 bound to carrier proteins persists much longer. By reducing that binding, the LR3 changes are intended to shift the balance toward a longer active window than native IGF-1 (IGF-1 LR3, Wikipedia). That is a design goal, not a confirmed human pharmacokinetic figure. Rather than repeat a specific hours value that has no trial behind it, the accurate statement is that human half-life data for IGF-1 LR3 are not available.

What side effects does IGF-1 research report?

Because IGF-1 shares actions with insulin, the most discussed theoretical concern is low blood sugar, and axis-raising compounds have shown metabolic trade-offs in trials, but direct human safety data for IGF-1 LR3 are not established.

A few points worth separating:

• Low blood sugar: IGF-1 has insulin-like activity, so hypoglycemia is a frequently raised theoretical concern. This is mechanism-based reasoning, not a finding from an IGF-1 LR3 trial.
• Glucose handling on the axis: raising GH and IGF-1 is not metabolically neutral. In healthy older adults, MK-677 raised fasting glucose and lowered insulin sensitivity at 25 mg/day (Nass et al., Ann Intern Med 2008; PMID 18981485), which shows the axis can shift how the body manages sugar.
• Long-term unknowns: the relationship between sustained high IGF-1 and cell-growth signaling is an open research topic that no IGF-1 LR3 trial answers. Without human trials of the analog, its own side-effect profile is uncertain.

The accurate reading is that the risk picture for IGF-1 LR3 specifically is undefined, and questions about it belong with a qualified clinician.

How does IGF-1 LR3 compare to MK-677 for muscle and recovery?

They target the same axis from opposite ends: IGF-1 LR3 is a direct IGF-1 analog with no human trials, while MK-677 is an oral secretagogue that raised the body's own GH and IGF-1 but also worsened glucose control in a controlled study (Nass et al., Ann Intern Med 2008).

The practical difference for anyone researching muscle and recovery is evidence quality. MK-677 has published human data, including a metabolic caution worth taking seriously: fasting glucose rose and insulin sensitivity fell. IGF-1 LR3 has essentially none, so claims about it borrow from IGF-1 biology in general rather than from tests of the compound. If you are weighing the two, you are weighing a compound with real human trial signals against one without them. See the MK-677 guide and the broader peptides for muscle growth overview for how these sit next to other options, and what are peptides for the wider category.

Is IGF-1 LR3 approved for people?

No: IGF-1 LR3 is distributed as a research reagent, and no health authority has cleared this specific analog as a human therapeutic. Reference records list no ATC code and no approved medical use (IGF-1 LR3, Wikipedia).

That regulatory status is a large part of why the compound appears in laboratories rather than clinics, and why the human data are thin. It is also why this page does not offer a dose or a protocol. A qualified clinician is the right person to weigh any decision, and there is no research-reported human figure to anchor to in the first place. For related axis compounds with published human data, see the CJC-1295 and Ipamorelin guide and the tesamorelin guide.